Tildrakizumab 100 mg (one 1-ml injection of 100 mg/ml    (DrugBank: Tildrakizumab)

1 disease
IDDisease name (Link within this page)Number of trials
271Ankylosing spondylitis1

271. Ankylosing spondylitis    [ 531 clinical trials,   343 drugs,   (DrugBank: 66 drugs),   41 drug target genes,   141 drug target pathways]
Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 531 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03552276
(ClinicalTrials.gov)
July 11, 20184/5/2018A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.Psoriatic Arthritis;Ankylosing Spondylitis;Non-Radiographic Axial SpondyloarthritisDrug: tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL);Drug: tildrakizumab 100 mg (one 1-mL injection of 100 mg/mL + 1 mL placebo)Sun Pharma Global FZENULLActive, not recruiting18 YearsN/AAll540Phase 2;Phase 3United States;Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine